Loading clinical trials...
Loading clinical trials...
Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determi...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sigma-Tau Research, Inc.
Collaborators
NCT06823167 · Solid Malignancies, Hematologic Malignancies
NCT06927297 · Advanced Solid Tumor Malignancies, Advanced Solid Malignancies
NCT06725381 · Solid Malignancies
NCT06600789 · Solid Malignancies
NCT06684028 · Cancer, Solid Malignancies
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Rhode Island Hospital
Providence, Rhode Island
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions